A scoping review of active, participant centred, digital adverse events following immunization (AEFI) surveillance of WHO approved COVID-19 vaccines: A Canadian immunization Research Network study
ABSTRACTThis scoping review examines the role of digital solutions in active, participant-centered surveillance of adverse events following initial release of COVID-19 vaccines. The goals of this paper were to examine the existing literature surrounding digital solutions and technology used for acti...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_f9ac0564af6e4021a0f9de9465e2a5f5 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Mohamed Serhan |e author |
| 700 | 1 | 0 | |a Athanasios Psihogios |e author |
| 700 | 1 | 0 | |a Nooh Kabir |e author |
| 700 | 1 | 0 | |a A. Brianne Bota |e author |
| 700 | 1 | 0 | |a Salima S. Mithani |e author |
| 700 | 1 | 0 | |a David P. Smith |e author |
| 700 | 1 | 0 | |a David T. Zhu |e author |
| 700 | 1 | 0 | |a Devon Greyson |e author |
| 700 | 1 | 0 | |a Sarah Wilson |e author |
| 700 | 1 | 0 | |a Deshayne Fell |e author |
| 700 | 1 | 0 | |a Karina A. Top |e author |
| 700 | 1 | 0 | |a Julie A. Bettinger |e author |
| 700 | 1 | 0 | |a Kumanan Wilson |e author |
| 245 | 0 | 0 | |a A scoping review of active, participant centred, digital adverse events following immunization (AEFI) surveillance of WHO approved COVID-19 vaccines: A Canadian immunization Research Network study |
| 260 | |b Taylor & Francis Group, |c 2024-12-01T00:00:00Z. | ||
| 500 | |a 10.1080/21645515.2023.2293550 | ||
| 500 | |a 2164-554X | ||
| 500 | |a 2164-5515 | ||
| 520 | |a ABSTRACTThis scoping review examines the role of digital solutions in active, participant-centered surveillance of adverse events following initial release of COVID-19 vaccines. The goals of this paper were to examine the existing literature surrounding digital solutions and technology used for active, participant centered, AEFI surveillance of novel COVID-19 vaccines approved by WHO. This paper also aimed to identify gaps in literature surrounding digital, active, participant centered AEFI surveillance systems and to identify and describe the core components of active, participant centered, digital surveillance systems being used for post-market AEFI surveillance of WHO approved COVID-19 vaccines, with a focus on the digital solutions and technology being used, the type of AEFI detected, and the populations under surveillance. The findings highlight the need for customized surveillance systems based on local contexts and the lessons learned to improve future vaccine monitoring and pandemic preparedness. | ||
| 546 | |a EN | ||
| 690 | |a Adverse events following immunization (AEFI) | ||
| 690 | |a vaccine safety surveillance | ||
| 690 | |a active surveillance | ||
| 690 | |a post-marketing surveillance | ||
| 690 | |a participant reporting | ||
| 690 | |a pharmacovigilance | ||
| 690 | |a Immunologic diseases. Allergy | ||
| 690 | |a RC581-607 | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024) | |
| 787 | 0 | |n https://www.tandfonline.com/doi/10.1080/21645515.2023.2293550 | |
| 787 | 0 | |n https://doaj.org/toc/2164-5515 | |
| 787 | 0 | |n https://doaj.org/toc/2164-554X | |
| 856 | 4 | 1 | |u https://doaj.org/article/f9ac0564af6e4021a0f9de9465e2a5f5 |z Connect to this object online. |